A double‐blind randomised trial to evaluate the effect of anastrozole for the treatment of non‐toxic multinodular goitre

J. S. Knight,R. Satchidanand,C. Yiangou,A. Jackson,M. Cummings
DOI: https://doi.org/10.1111/j.1742-1241.2006.00985.x
IF: 2.6
2006-06-02
International Journal of Clinical Practice
Abstract:Multinodular goitre (MNG) is a common clinical finding, particularly in females and is usually asymptomatic. When symptoms occur because of local pressure‐related effects the only treatment is surgical involving partial or total thyroidectomy. A number of epidemiological observations and experimental data have suggested that oestrogen aromatase activity may be involved in the pathogenesis of MNG. This study examines the effect of anastrozole, a non‐steroidal aromatase inhibitor that inhibits the peripheral conversion of testosterone to oestradiol, in reducing the size of MNG. Thirty‐two post‐menopausal female patients, median age 63 years (range 42–84) were randomised in a double‐blind fashion to receive either anastrozole 1 mg daily or placebo for 3 months. Ultrasonographic measurement of each thyroid lobe and isthmus together with complete biochemical and hormone profiles were performed at the start and end of treatment. There was no significant reduction in the goitre size for patients in the anastrozole group (p = 0.246) or the placebo group (p = 0.418). There were no significant changes in hormone profiles (including throglobulin concentration) within each group between the start and end of the study. We conclude that the use of anastrozole in the treatment of MNG does not appear to have any effect in reducing the size of MNG.
What problem does this paper attempt to address?